Skip to content

Arcutis Biotherapeutics, Inc. ARQT Net Investment in Lease

Net Investment in Lease at other companies

Kymera Therapeutics logo
Kymera TherapeuticsKYMR
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
LQD
Liquidia CorporationLQDA
TG Therapeutics logo
TG TherapeuticsTGTX
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s net investment in lease?
Arcutis Biotherapeutics, Inc. (ARQT) reported net investment in lease of $4.36M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s net investment in lease changed year-over-year?
Arcutis Biotherapeutics, Inc.'s net investment in lease increased by 136.8% year-over-year, from $1.84M to $4.36M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s net investment in lease?
Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s net investment in lease has grown at a 5.9% compound annual growth rate (CAGR), from $3.35M to $4.47M.